 Home > Medical News > Medicines Company News > Hanyu Pharmaceutical's HY3000 nasal spray obtained the ethical approval of the phase II clinical trial team leader

Hanyu Pharmaceutical's HY3000 nasal spray obtained the ethical approval of the phase II clinical trial team leader

 Last Update: 2023-01-01
 Source: Internet
 Author: User

Tags

human body poster

phenylephrine nasal spray

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 02, 2022, the phase II clinical research protocol of HY3000 nasal spray of Shenzhen Hanyu Pharmaceutical Co.
, Ltd.
was approved by the team leader of the Medical Ethics Committee of Zhujiang Hospital of Southern Medical University (approval number: 2022-YW-075-02).

This study is a randomized, double-blind, placebo-controlled phase II clinical study
evaluating the efficacy and safety of HY3000 nasal spray for pre-exposure prophylaxis against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection.
The phase II clinical research protocol has recently been submitted to the medical ethics committee of Zhujiang Hospital of Southern Medical University for review and approval
.

HY3000 is a membrane fusion inhibitor polypeptide that acts on the HR1 region of the new coronavirus spike protein, and by binding to the HR1 region, prevents the formation of the virus hexahelix bundle structure and blocks the path
of virus infection cells.
The dosage form developed in this project is nasal spray, which can establish an antiviral defense line on the primary path of virus invasion of the human body through nasal administration, and block the new coronavirus infection
.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.